Home Tags Brentuximab Vedotin

Tag: Brentuximab Vedotin

Brentuximab Vedotin Receives European Commission Approval for CD30-Positive Cutaneous T-Cell Lymphoma...

The European Commission has extended the current conditional marketing authorization for brentuximab vedotin (Adcetris®; Takeda/Seattle Genetics) to include the treatment of adult patients with...

The Expanding Field of Antibody-Drug Conjugates

Antibody-drug conjugates or ADCs have emerged as a powerful and strategy tool in the targeted treatment of cancer.  These relatively novel agents combine the...

U.S. FDA Grants Priority Review for Brentuximab Vedotin in Frontline Advanced...

Based on positive results from the Phase III ECHELON-1 clinical trial, the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental...
Featured Image: American Society of Hematology | Annual Meeting. Courtesy: © 2017. American Society of Hematology. Used with permission.

Phase III ECHELON-1 Clinical Trial of Brentuximab Vedotin Meets Primary Endpoint...

Data from the Phase III ECHELON-1 clinical trial evaluating brentuximab vedotin (Adcetris®; Seattle Genetics | Takeda) as part of a frontline combination chemotherapy regimen...

Long-term Data of Brentuximab Vedotin Redifines Treatment of Frontline Mature T-Cell...

Data highlighted at the 59th annual meeting of the American Society of Hematology (ASH) held in Atlanta, Georgia, December 9-12, 2017 shows final five-year...

Antibody-Drug Conjugates at the 59th American Society of Hematology Annual...

This year, in Atlanta, the South's largest and most vibrant city, the 59th annual meeting and exposition of the American Society of Hematology, to...

FDA Approves Label Expansion for Brentuximab Vedotin

The approval of brentuximab vedotin (Adcetris®; Seattle Genetics) for the treatment of adult patients with primary cutaneous anaplastic Large cell lymphoma or pcALC, which...

Supplemental Biologics License Application for Brentuximab Vedotin in Frontline Advanced Hodgkin...

Based on positive results from the Phase III ECHELON-1 Clinical Trial evaluating brentuximab vedotin (Adcetris®; Seattle Genetics) in combination with chemotherapy for the frontline...

Long-Term Data Continues to Support Development Strategy to Establish Brentuximab Vedotin...

Final data from the pivotal phase II trial with brentuximab vedotin (Adcetris®; Seattle Genetics/Takada)   in relapsed* or refractory** (r/r) systemic anaplastic large cell lymphoma (sALCL)...

Positive Phase III ECHELON-1 Trial Data Leads to FDA Breakthrough Therapy...

U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to brentuximab vedotin (Adcetris®; Seattle Genetics) in combination with chemotherapy for the frontline...